VistaGen and Leading Stem Cell Researchers Pinpoint Key Biochemical Pathways Involved in Generating Large Numbers of Heart Cells From Embryonic Stem Cells
Posted on: Wednesday, 15 October 2008, 15:00 CDT
Researchers from VistaGen Therapeutics, together with Dr. Gordon Keller and his team of scientists from Toronto's McEwen Centre for Regenerative Medicine and the Mount Sinai School of Medicine, have successfully identified key biochemical pathways involved in directing embryonic stem (ES) cells to become heart cells.
The research was published recently in the online edition of the scientific journal Nature Biotechnology, in a paper entitled "Notch signaling re-specifies the hemangioblast to a cardiac fate."
Dr. Ralph Snodgrass, VistaGen's CEO, said, "The objective of this study was to better understand the development of heart cells, and improve approaches to direct ES cells to become heart cells. The published paper shows that by coordinating the signaling of certain molecular pathways we can produce large numbers of functional, highly pure, heart cells for improved drug safety screening and development."
Along with VistaGen scientists, the research team was headed by Dr. Gordon Keller, Director of the McEwen Centre for Regenerative Medicine, an important component of Toronto's University Health Network (UHN). Dr. Vincent Chen, currently at the Black Family Stem Cell Institute at New York's Mount Sinai School of Medicine, a postdoctoral fellow in Dr. Keller's group, was the lead author in the study. VistaGen has collaborated with Dr. Keller, one of the world's leading stem cell scientists, on research projects for more than 10 years. In March, 2008, VistaGen announced an expansive new ES cell research alliance with Dr. Keller, UHN and the McEwen Centre.
About VistaGen Therapeutics
VistaGen Therapeutics enables the pharmaceutical industry to transform its preclinical development approaches through the company's human ES cell systems biology platform, which can dramatically improve R&D productivity, reduce clinical development failures, and lower drug development costs. Through its "Clinical Trials in a Test Tube(TM)" approach, VistaGen's industry advantage is its ability to support early heart and liver safety screening, reduce opportunity cost of clinical failures and non-viable drug candidates, and expedite development of promising drug candidates.
Source: Business Wire
Related Articles
- Yingli Green Energy, Energy Research Centre of the Netherlands and Amtech Systems Announce Research Collaboration to Develop Next Generation High Efficiency Solar Cells
- Mouse Embryonic Stem Cells Build a Heart
- Advanced Cell Technology's Dr. Robert Lanza Testifies Before U.S. Senate Subcommittee; Testimony Discusses How Company's Technique for Human Stem Cell Development May Advance Support for Stem Cell Research
- Geron, University of Edinburgh Form Collaboration for Development of Three Cell Types Derived From Human Embryonic Stem Cells
- Stem Cells Develop into Human Brain Cells in Mice: Study
- China Develops Typing Reagent of Hematopoietic Stem Cell
- Markers of Brain Cell Development May Help Success of Stem Cell Transplants
- Trial to Test Stem Cells for Heart Attacks
- Researchers Identify Genes Involved with Blood Stem Cell Development
- Embryonic Stem Cells Keep Heart Beating
 |
 |
User Comments (0)
RSS Feeds